Business Context and Reporting Period
Sunshine Biopharma Inc., a small business issuer incorporated in Colorado with principal offices in Montreal, Canada, filed this Form 8-K on June 2, 2010. The report discloses an unregistered sale of equity securities effective as of the filing date.
Key Financial Metrics
The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity. The transaction involved the issuance of 1,675,000 shares of restricted Common Stock in exchange for services. The company explicitly stated it did not receive any cash compensation as a result of these issuances.
Material Changes
The primary material change is the authorization and issuance of 1,675,000 shares of restricted Common Stock to various consultants. This issuance was made under the exemption from registration provided by Section 4(2) of the Securities Act of 1933. The breakdown of shares issued is as follows:
- The Video Agency, Inc.: 375,000 shares for Advertising
- Brockington Securities, Inc.: 300,000 shares for Financial Consulting
- Insight Capital Consultants Corporation: 650,000 shares for Financial Consulting
- Alchemy Financial Services Inc.: 300,000 shares for Public Relations
- CJR Capital Advisors Inc.: 50,000 shares for Financial Consulting
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the unregistered sale. The transaction is noted as a non-cash compensation event.
Investor Verification Checklist
- Verify the valuation assigned to the 1,675,000 shares issued for services to assess potential dilution impact.
- Confirm the specific terms and duration of the consulting agreements with the five recipient entities.
- Review the company's total outstanding share count to calculate the percentage dilution from this issuance.
- Check for any subsequent filings regarding the vesting schedules or restrictions on these shares.